Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

The Food and Drug Administration has approved Nereus (tradipitant) for the prevention of vomiting induced by motion in adults.

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment ...

The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked ...

In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...

The scopolamine skin patch (Transderm Scōp), approved in 1979, was the last drug sanctioned by the FDA to prevent motion ...

Motion sickness is something that has troubled most of us. While some may get over the feeling with time, others may continue to battle the woes of motion sickness throughout their life. "Motion ...

Motion sickness is an unpleasant sensation commonly seen in some vulnerable individuals when they are subjected to unnatural motion. All persons can develop motion sickness if given the right stimulus ...